NCT07133386尚未招募不适用
TRUST Trial Protocol
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Kansas City Cardiomyopathy Questionnaire
研究概览
简要总结
This is a multicentre, randomised, placebo-controlled trial conducted at St Bartholomew's Hospital, John Radcliff Hospital, Royal Brompton Hospital, and Kings College London Hospital. The aim is to evaluate the benefits in health status from transcatheter edge to edge repair with the TriClip device in patients with severe or more symptomatic tricuspid regurgitation. A total of 150 patients will be recruited in a 1:1 ratio for TriClip or placebo. The primary endpoint of this study (change in Kansas City Cardiomyopathy Questionnaire between the treatment and placebo arm) will be analysed using a linear mixed model and compared between patients who receive the TriClip versus those who have a placebo procedure.
Study duration: 3 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged >18 years at recruitment
- •Severe or more symptomatic TR determined by transthoracic echocardiography
- •Optimized medical and/or device therapy for a minimum of 30 days
- •Medications, including diuretics should be stable over the past 30 days
- •Baseline KCCQ 75 or less on minimum 2 assessments at least 2 weeks apart
- •New York Heart Association (NYHA) Functional Class II or ambulatory class IV
- •Morphology of tricuspid valve suitable for TEER with expectation of a reduction of severity of TR to moderate or less
- •Willing to provide written informed consent
排除标准
- •Presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results or result in an expected life expectancy of less than 12 months
- •Active malignancy associated with a prognosis of <1 year
- •Left ventricular ejection fraction (LVEF)<20%
- •Tricuspid valve leaflet anatomy which may preclude TriClip implantation, proper clip positioning on the leaflets or sufficient reduction in TR. This may include:
- •Evidence of calcification in the grasping area
- •Presence of a severe coaptation defect (>10mm) of the tricuspid leaflets. - Severe leaflet defect(s) preventing proper device placement
- •Ebstein Anomaly - Identified by having a normal annulus position while the valve leaflets are attached to the walls and septum of the right ventricle.
- •Tricuspid valve anatomy not evaluable by transthoracic (TTE) or transoesophageal echo (TOE)
- •Rheumatic heart disease affecting the tricuspid valve
- •Indication for left-sided (e.g. severe aortic stenosis, severe mitral regurgitation) or pulmonary valve correction. Note: Patients with concomitant mitral and tricuspid valve disease will have the option of having any significant mitral regurgitation managed, then waiting 60 days prior to being reassessed for the current trial.
- •Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the TriClip.
- •Tricuspid valve stenosis - Defined as a tricuspid valve orifice of ≤ 3.0 cm2 and/or mean gradient ≥3 mmHg as measured by the transthoracic echocardiography
- •Unable to comply with study protocol
- •Uncontrolled systemic hypertension with a systolic blood pressure >180mmHg or diastolic blood pressure >110mmHg
- •Severe pulmonary hypertension (sPAP>70mmHg) or fixed pre-capillary pulmonary hypertension assessed by cardiac catheterization
- •Stroke within prior 90 days
- •Chronic dialysis
- •Bleeding disorders or hypercoagulable state
- •Active peptic ulcer or active gastrointestinal (GI) bleeding
- •Ongoing infection requiring current antibiotic therapy (if temporary illness, patients may enrol 30 days after discontinuation of antibiotics with no active infection).
- •Known allergy or hypersensitivity to device materials
- •Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
- •Enrolment in another clinical trial that involves treatment of tricuspid regurgitation
结局指标
主要结局
Kansas City Cardiomyopathy Questionnaire
时间窗: every 2 weeks twice before the intervention and for 3 months post-intervention
health status questionnaire
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Health professional Administered Brief Insomnia Therapy (HABIT) trialMental and Behavioural DisordersDisorders of initiating and maintaining sleep [insomnias]InsomniaISRCTN42499563niversity of Oxford642
已完成
2 期
Study of XL784 in Patients With Albuminuria Due to Diabetic NephropathyAlbuminuriaDiabetic NephropathyNCT00312780Symphony Evolution, Inc.125
已完成
2 期
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea TypeIrritable Bowel Syndrome of Diarrhea Type (IBS-D)NCT05923892Otsuka Beijing Research Institute87
终止
3 期
Tepilta® Versus Oxetacaine, Antacids and PlaceboRadiation-induced OesophagitisNCT01336530MEDA Pharma GmbH & Co. KG40
进行中（未招募）
不适用
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt SystemHeart FailureNCT05686317Edwards Lifesciences100